reports
- Javier Esteban
INTESA SANPAOLO: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)
Rdos. 1T'24 vs 1T'23: M. Intereses: 3.932 M euros (+20,8% vs +19,9% BS(e) y +20,5% consenso); M. Bruto: 6.732 M euros (+11,1% vs +8,4% BS(e) y +9,2% consenso); M. Neto: 4.162 M euros (+18,2% vs +9,8% BS(e) y +11,8% consenso); BDI: 2.301 M euros (+17,6% vs +13,4% BS(e) y n/a consenso). Rdos. 1T'24 vs 4T'23: M. Intereses: 3.932 M euros (-1,6% vs -2,4% BS(e) y -1,9% consenso); M. Bruto: 6.732 M euros (+5,6% vs +3,0% BS(e) y +3,8% consenso); M. Neto: 4.162 M euros (+43,3% vs +33,1% BS(e) y +35,6% co...
- Jerôme Bodin
LR LEGRAND SA
FRA FRAPORT AG
LI KLEPIERRE SA
ALV ALLIANZ SE
ORSTED ORSTED
RAA RATIONAL AG
INGA ING GROEP NV
SAN BANCO SANTANDER S.A.
IHG INTERCONTINENTAL HOTELS GROUP PLC
MRNA MODERNA INC.
VWS VESTAS WIND SYSTEMS
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
DTG DAIMLER TRUCK
LIN LINDE PUBLIC LIMITED COMPANY
SHUR SHURGARD SELF STORAGE LIMITED
- Bruno Cavalier
- Jerôme Bodin
LR LEGRAND SA
FRA FRAPORT AG
LI KLEPIERRE SA
ALV ALLIANZ SE
ORSTED ORSTED
RAA RATIONAL AG
INGA ING GROEP NV
SAN BANCO SANTANDER S.A.
IHG INTERCONTINENTAL HOTELS GROUP PLC
MRNA MODERNA INC.
VWS VESTAS WIND SYSTEMS
UMG UNIVERSAL MUSIC GROUP NV
DSY DASSAULT SYSTEMES SA
DTG DAIMLER TRUCK
LIN LINDE PUBLIC LIMITED COMPANY
SHUR SHURGARD SELF STORAGE LIMITED
- Dominic Rose
- Naresh Chouhan
Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)
This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...
- Nicolas David
Dassault Systemes : 3DExperience should drive the acceleration in grow...
>A reasonably optimistic tone on Medidata - As expected, a significant part of the discussions with the CFO during this roadshow focused on the difficulties of Medidata (15% of Group sales). In Q2, the Medidata growth trend should be in line with Q1 (-2.5% cc). That said, Dassault Systèmes’ management sees signs of improvement on the commercial front: i/ bookings linked to the volume of clinical trials are up slightly; ii/ demand at mid-sized clients is stabilising an...
- Nicolas David
Dassault Systèmes : La 3DExperience va tirer l’accélération de la croi...
>Ton raisonnablement optimiste concernant Medidata - Comme attendu, une part importante des discussions avec le CFO lors de ce roadshow a porté sur les difficultés de Medidata (15% CA groupe). La croissance T2 de Medidata devrait s’inscrire dans la lignée du T1 (-2.5% cc). Néanmoins, le management de DSY voit quelques signes d’amélioration sur le plan commercial : 1/ les bookings liés aux volumes d’essais cliniques sont en légère croissance ; 2/ la demande auprès des ...
Hermes International: 1 director
A director at Hermes International bought 1,220 shares at 2,298.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Disclosure Of the Number of Shares Forming the Capital and of the Tota...
Disclosure Of the Number of Shares Forming the Capital and of the Total Number of Voting Rights as of 30 April 2024 French public limited company (société anonyme)with a share capital of €1,473,943,102.50Registered office : 1973, boulevard de la Défense92000 Nanterre – France552 037 806 RCS Nanterre DISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTSAS OF 30 APRIL 2024 Total number of shares589,577,241Theoretical number of voting rights (including treasury stock)589,577,241Number of voting rights (excluding treasury stock)571,192,066 This disclosu...
VINCI to take part in the Great Grid Partnership programme in the Unit...
VINCI to take part in the Great Grid Partnership programme in the United Kingdom Nanterre, 02 May 2024 VINCI to take part in the Great Grid Partnership programme in the United Kingdom. OTW, a joint-venture between VINCI Energies and VINCI Construction in the UK, has been set up A set of several projects to connect the British grid to the new offshore wind farms by 2030 VINCI, through OTW, selected to take part in these projects In the United Kingdom, Omexom UK & RoI (subsidiary of VINCI Energies) and Taylor Woodrow (subsidiary of VINCI Construction), have set up a joint-venture, OTW, ...
- Cedric Rossi
adidas: The best sunny terrace in sporting goods currently...
During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We
Press Release: Beyfortus real-world evidence published in The Lancet s...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...
Communiqué de presse : Des données de vie réelle concernant Beyfortus ...
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...
Kering Sa: 2 directors
Two Directors at Kering Sa bought 135,294 shares at between 327.936EUR and 337.639EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Sanofi: 1 director
A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
New Dassault Systèmes Media Campaign Introduces Virtual Worlds for Rea...
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- (Euronext Paris: FR0014003TT8, DSY.PA) today announced the launch of a digital out-of-home media campaign inviting three million people in London to see and understand how virtual worlds are impacting real life in areas such as health, cities and manufacturing. This press release features multimedia. View the full release here: From April 28-May 5, Piccadilly Circus will be illuminated by a massive, 780-square-meter screen showcasing groundbreaking innovations created with Dassault Systèmes’ virtual twin technology, highlighting how imagination...
Lvmh Moet Hennessy Louis Vuitton SE: 1 director
A director at Lvmh Moet Hennessy Louis Vuitton SE bought 16,134 shares at 785.866EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
EssilorLuxottica: EssilorLuxottica 2024 Annual Shareholders’ Meeting, ...
EssilorLuxottica: EssilorLuxottica 2024 Annual Shareholders’ Meeting, starting a new chapter of the Company’s history EssilorLuxottica 2024 Annual Shareholders’ Meeting,starting a new chapter of the Company’s history All resolutions proposed by the Board of Directors adoptedDividend of Euro 3.95 per share, with option for payment in sharesAll directors re-appointed to the new Board of DirectorsFrancesco Milleri and Paul du Saillant confirmed as Chairman and CEO and Deputy CEO Charenton-le-Pont, France (April 30, 2024 – 6:00 pm CEST) – EssilorLuxottica Annual Shareholders’ Meeting was held...
EssilorLuxottica: Assemblea Annuale degli Azionisti 2024, inizia un nu...
EssilorLuxottica: Assemblea Annuale degli Azionisti 2024, inizia un nuovo capitolo della storia di EssilorLuxottica Assemblea Annuale degli Azionisti 2024,inizia un nuovo capitolo della storia di EssilorLuxottica Approvate tutte le delibere proposte dal Consiglio di AmministrazioneDividendo pari a Euro 3,95 per azione, con opzione per il pagamento in azioniRiconferma di tutti gli attuali Amministratori per il nuovo Consiglio di AmministrazioneFrancesco Milleri e Paul du Saillant confermati nei rispettivi ruoli di Presidente e Amministratore Delegato e Vice Amministratore Delegato Ch...
Press Release: Annual General Meeting of April 30, 2024
Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2023Distribution d’un dividende en numéraire de 3,76 euros par action, dont la mise en paiement interviendra le 15 mai 2024Composition du Conseil d’administration : renouvellement de deux administrateurs et nomination de trois nouveaux administrateurs indépendants Paris, le 30 avril 2024. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2024, sous la présidence de Frédéric ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.